Guardant Health Inc. presented an update from its LUNAR-2 liquid biopsy testing programs to detect early-stage colorectal cancer at this week’s American Association for Cancer Research (AACR) virtual meeting.
The Redwood City, CA-based company continues to weather the impact of the COVID-19 pandemic, which led to a delay in enrolling participants in the ECLIPSE trial. The trial is...